At close: December 13 at 1:30:06 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16,705,227.00
14,200,068.00
10,494,470.00
4,899,885.00
1,799,570.00
Cost of Revenue
9,175,262.00
7,208,830.00
7,581,695.00
3,228,107.00
1,095,686.00
Gross Profit
7,529,965.00
6,991,238.00
2,912,775.00
1,671,778.00
703,884.00
Operating Expense
3,542,193.00
1,742,099.00
990,599.00
625,787.00
477,807.00
Operating Income
3,987,772.00
5,249,139.00
1,922,176.00
1,045,991.00
226,077.00
Net Non Operating Interest Income Expense
-397,165.00
-171,239.00
-108,727.00
-53,616.00
-21,973.00
Pretax Income
4,891,465.00
4,064,146.00
1,840,001.00
1,023,968.00
595,399.00
Tax Provision
897,109.00
992,225.00
438,476.00
274,232.00
16,973.00
Net Income Common Stockholders
3,900,162.00
3,030,142.00
1,391,916.00
749,736.00
578,426.00
Diluted NI Available to Com Stockholders
3,900,162.00
3,030,142.00
1,391,916.00
749,736.00
578,426.00
Basic EPS
38.44
30.20
14.26
7.73
6.04
Diluted EPS
37.07
29.39
14.13
7.71
6.00
Basic Average Shares
101,369.25
100,341.00
97,600.00
77,852.38
95,773.71
Diluted Average Shares
106,058.25
103,560.00
98,698.00
78,083.58
96,502.68
Total Expenses
12,717,455.00
8,950,929.00
8,572,294.00
3,853,894.00
1,573,493.00
Net Income from Continuing & Discontinued Operation
3,900,162.00
3,030,142.00
1,391,916.00
749,736.00
578,426.00
Normalized Income
2,683,611.20
3,030,142.00
1,391,916.00
749,736.00
201,621.73
Interest Expense
397,165.00
171,239.00
108,727.00
53,616.00
21,973.00
Net Interest Income
-397,165.00
-171,239.00
-108,727.00
-53,616.00
-21,973.00
EBIT
5,288,630.00
4,235,385.00
1,948,728.00
1,077,584.00
617,372.00
EBITDA
6,171,675.00
4,841,671.00
2,273,914.00
1,287,749.00
758,399.00
Reconciled Cost of Revenue
9,175,262.00
7,208,830.00
7,581,695.00
3,228,107.00
1,095,686.00
Reconciled Depreciation
883,045.00
606,286.00
325,186.00
210,165.00
141,027.00
Net Income from Continuing Operation Net Minority Interest
3,900,162.00
3,030,142.00
1,391,916.00
749,736.00
578,426.00
Total Unusual Items Excluding Goodwill
1,489,781.00
--
--
--
387,861.00
Total Unusual Items
1,489,781.00
--
--
--
387,861.00
Normalized EBITDA
4,681,894.00
4,841,671.00
2,273,914.00
1,287,749.00
370,538.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
273,230.20
--
--
--
11,056.73
12/31/2020 - 12/11/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6446.TW PharmaEssentia Corporation
585.00
-1.85%
1795.TW Lotus Pharmaceutical Co., Ltd.
261.00
-1.51%
4123.TWO Center Laboratories, Inc.
42.95
-1.72%
4746.TW Formosa Laboratories, Inc.
71.30
-1.25%
6785.TWO Alar Pharmaceuticals Inc.
146.00
-2.34%
4120.TWO Orient EuroPharma Co., Ltd.
48.50
-8.14%
4105.TWO TTY Biopharm Company Limited
73.20
-1.48%
4114.TWO Synmosa Biopharma Corporation
33.00
-1.49%
4119.TW SCI Pharmtech, Inc.
90.60
-2.05%
1799.TWO Easywell Biomedicals, Inc.
54.90
0.00%